Evofem shares surge as contraceptive gel meets late-stage trial goal

Shares of Evofem Biosciences Inc jumped as much as 38 percent on Monday after its birth control gel showed effectiveness in a late-stage study, bringing the first hormone-free contraceptive close to approval.